Dengue Vaccine: Why Mendoza Won’t Be Vaccinating

Mendoza Holds Off on Dengue Vaccine Despite Early Cases

Mendoza, Argentina – As the first cases of dengue fever emerge in Mendoza earlier than usual this year, the province is ‍taking a cautious approach to vaccination. While other provinces are moving forward ⁢with vaccination programs using doses provided by the national government or through their own purchases, Mendoza will not be administering the dengue vaccine at this time.

Health Minister Rodolfo Montero reiterated the province’s stance during a press conference Friday, prior to a training session for journalists on dengue prevention and control. He cited two primary reasons for Mendoza’s decision: the province doesn’t currently meet the epidemiological criteria for vaccination, and the vaccine is still undergoing ⁤Phase⁤ 4 clinical trials.

The national government’s Plan estratégico de Prevención y Control de Dengue 2024-2025 allocated 160,000 doses to 48 ⁢high-risk departments ⁣across⁢ 11 provinces. These areas were selected based⁣ on year-round‍ dengue circulation and a high incidence rate of over 4,200 cases per 100,000 inhabitants.

Mendoza’s current dengue situation does not meet these criteria, leading the province to hold ‍off on vaccination for⁤ now.

Mendoza⁣ Holds Off on Dengue Vaccine Despite Early Cases

Mendoza, argentina – Mendoza province is taking a cautious approach to dengue vaccination, despite the early emergence of dengue fever cases this year. While other provinces have initiated vaccination programs using ‍doses provided by the ⁤national ⁣government or⁣ purchased independently, Mendoza will not be administering the dengue vaccine at this time.

Health Minister Rodolfo Montero ⁢clarified the province’s position during a Friday press conference preceding ⁢a training session for journalists on dengue prevention and control. He attributed Mendoza’s decision to two main factors: the province hasn’t satisfied epidemiological ⁤criteria for vaccination, and the vaccine remains in Phase 4 clinical trials.

The national government’s ‘Plan estratégico de Prevención⁤ y Control ⁤de Dengue 2024-2025’ allocated ⁢160,000 doses ‍to 48 high-risk departments across 11 provinces. These areas where selected based⁣ on year-round‍ dengue circulation and a high incidence rate‍ exceeding 4,200⁢ cases per ⁢100,000 inhabitants.

Mendoza’s ⁢current dengue situation dose not align ⁤with these ⁢criteria, prompting⁣ the ‍province to postpone vaccination temporarily.